Chase Pharmaceuticals
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $1.2m | Series A | |
$21.0m | Series B | ||
N/A | $3.0m | Debt | |
N/A | $3.5m | Series B | |
$125m Valuation: $125m | Acquisition | ||
Total Funding | $25.7m |
Related Content
Recent News about Chase Pharmaceuticals
EditChase Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, with a primary focus on Alzheimer's disease. The company operates in the healthcare and pharmaceutical market, targeting patients suffering from debilitating neurological conditions. Chase Pharmaceuticals employs a research-driven business model, leveraging advanced scientific methodologies to create effective therapeutic solutions. The company generates revenue through the development, approval, and commercialization of its pharmaceutical products. By addressing unmet medical needs, Chase Pharmaceuticals aims to enhance the quality of life for patients and provide significant advancements in the treatment of neurodegenerative disorders.
Keywords: biopharmaceutical, neurodegenerative, Alzheimer's, healthcare, pharmaceutical, research-driven, therapeutic solutions, neurological conditions, patient outcomes, medical advancements.